Why Trials Matter Right Now
The pace of diabetes research has picked up considerably. In October 2025, the FDA approved oral semaglutide (Rybelsus) to reduce cardiovascular risk in adults with type 2 diabetes who are at high risk for heart problems. That decision came from the SOUL trial, which followed 9,650 participants aged 50 and older for four years and found the 14 mg dose lowered major cardiovascular events by 14% compared with placebo.
Around the same time, researchers at the University of Virginia began testing an AI-powered upgrade to automated insulin delivery systems. The new feature, called the Bolus Priming System with Reinforcement Learning, lets the system adjust insulin on its own during meals and overnight, without requiring the user to enter carbohydrate counts. Sixteen adults with type 1 diabetes are testing it over three weeks, and the early goal is simple: make blood sugar control less mentally taxing.
For people with type 2 diabetes who use insulin, the Omnipod 5 automated insulin delivery system was cleared by the FDA for adults 18 and older after a 13-week multicenter trial at 21 US centers. The study enrolled a deliberately diverse group, with participants ranging from 18 to 75 years old, and used continuous glucose monitoring to guide insulin adjustments automatically.
What these trials share is a shift toward convenience. The old model asked patients to fit their lives around rigid dosing schedules. The new one builds the schedule around real-life patterns — meals, stress, activity — and lets technology handle the rest.
The Treatments Making Headlines
Combination Therapies That Do More
A large ongoing study from Novo Nordisk is comparing CagriSema — a weekly combination of cagrilintide and semaglutide — against tirzepatide in people with type 2 diabetes who are already on metformin with or without an SGLT2 inhibitor. The trial follows participants for up to a year and a half, measuring both blood sugar reduction and weight loss. Results are expected to help doctors understand which patients benefit most from dual-action therapies.
Remission Through Weight Management
The DiRECT trial, while based in the UK, has influenced how US endocrinologists talk about remission. The five-year follow-up published in 2026 showed that participants who followed the Counterweight-Plus low-energy diet program lost about 6.1 kg on average, and roughly 10% maintained remission from type 2 diabetes at five years. Even more telling for Americans worried about healthcare costs: the intervention saved about $480 per participant per year in healthcare expenses, mostly through reduced hospital admissions.
Smarter Insulin Delivery
The JAMA-published Omnipod 5 study deserves a closer look for anyone managing insulin therapy. It enrolled a large, diverse population across 21 centers, used masked Dexcom G6 continuous glucose monitoring during a 14-day baseline phase, and then transitioned participants to automated insulin delivery for 13 weeks. Meal boluses were simplified — participants could choose small, medium, or large fixed doses instead of counting every carbohydrate. That flexibility matters because it removes one of the biggest barriers to insulin use.
| Trial or Treatment | What It Tests | Who It Is For | Key Outcomes | Considerations |
|---|
| SOUL / Oral semaglutide | Cardiovascular risk reduction with 7 mg and 14 mg tablets | Adults 50+ with type 2 diabetes and heart or kidney disease | 14% reduction in major cardiovascular events over 4 years | GI side effects more common; higher discontinuation rate |
| Omnipod 5 AID System | Tubeless automated insulin delivery with CGM | Adults 18–75 with insulin-treated type 2 diabetes | Improved glucose control over 13 weeks at 21 US centers | Requires comfort with wearable technology |
| UVA BPS_RL trial | AI reinforcement learning for insulin dosing | Adults with type 1 diabetes experienced with AID | Aims for fully automated dosing during meals and overnight | Early-stage; only 16 participants in current phase |
| CagriSema vs tirzepatide | Weekly dual-action injectable vs single-action | Type 2 diabetes on metformin with or without SGLT2 inhibitor | Blood sugar and weight outcomes over up to 1.5 years | Trial completed data collection; results pending |
| DiRECT / Counterweight-Plus | Structured low-energy diet for remission | Adults with type 2 diabetes and excess weight | ~10% remission at 5 years; lower annual healthcare costs | Requires intensive dietary commitment |
How to Find and Join a Diabetes Trial
Finding a study is easier than most people expect, and you do not need to live near a major research university to participate.
Start with ClinicalTrials.gov. Search by your condition, your state, and whether the study is currently recruiting. Most listings include eligibility criteria, the study location, and a contact person. Filter for studies in your area — "near me" searches work well here because many trials list zip code–based recruitment.
Check with your endocrinologist or primary care doctor. Physicians who treat diabetes regularly often hear about studies before they are publicly listed. Ask specifically about trials for your type of diabetes, your current medication, and any complications you manage. A doctor's referral can also help you qualify faster, since many trials require a stable medication history.
Look into academic medical centers in your region. The University of Virginia trial is a good example: it recruited participants who already used automated insulin delivery systems, which means they did not need to start from scratch. Large centers like Boston Children's Hospital run studies on diet and glucose control that welcome participants who are not existing patients. The type 1 diabetes diet study there, for instance, compares a standard diet with a very low carbohydrate approach over 12 weeks and provides all meals through a delivery service, with compensation up to $1,300 for time and effort.
Ask about compensation and support before you enroll. Many trials reimburse travel, parking, and lodging. Some provide meals, glucose monitors, or study medication at no cost. Compensation for time varies widely — some studies offer modest stipends, others are more substantial — and it is worth asking directly what financial support is available.
Understand the time commitment. A 13-week device trial means weekly data reviews and periodic in-person visits. A medication trial can run a year and a half with monthly check-ins. Make sure you can realistically attend the required visits before you sign anything.
What to Expect Once You Enroll
Every trial follows a similar rhythm. You will start with a screening visit that includes blood work, a review of your medical history, and a conversation about your current medication. If you qualify, you will receive detailed information about the study drug or device, the visit schedule, and what is expected of you.
During the study, your diabetes care is often handled by the research team in coordination with your regular doctor. In the Boston Children's diet study, for example, the research team takes over diabetes care during the 12-week period, reviewing glucose data weekly and adjusting insulin as needed. Your regular diabetes team stays informed and takes back over when the study ends.
Most trials allow you to withdraw at any time, for any reason, and you are compensated for the time you did complete. That flexibility makes participation less intimidating than many people assume.
The Bottom Line
Diabetes management is entering a phase where the options on the table are genuinely different from what was available a few years ago. Oral medications now carry heart benefits. Insulin pumps can think for themselves. Combination therapies are being compared head-to-head to find out which works better in the real world.
If you are living with diabetes and have wondered whether a trial might be right for you, the practical next step is simple: search ClinicalTrials.gov for studies in your state, mention your interest at your next doctor's appointment, and ask what compensation and support the study offers. The researchers running these trials need participants who represent the real diversity of people managing diabetes — different ages, backgrounds, medication histories, and daily routines. Your experience could be exactly the data point that helps shape the next generation of diabetes care.
研究の知恵